New inhaled drug shows promise for lung disease patients in Long-Term trial
NCT ID NCT05649748
First seen Oct 31, 2025 · Last updated Apr 22, 2026 · Updated 25 times
Summary
This study looks at the long-term safety of an inhaled powder called TPIP for people with pulmonary arterial hypertension (PAH), a serious lung condition. About 91 adults who completed earlier TPIP studies will take the drug and be monitored for side effects and changes in walking distance and blood markers. The goal is to see if TPIP remains safe and effective over time, but participants must continue taking medication to manage their disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ARG001
Córdoba, X5000FPQ, Argentina
-
ARG004
Córdoba, X5000DCE, Argentina
-
ARG006
Rosario, Santa Fe Province, S2013KDS, Argentina
-
ARG007
San Miguel de Tucumán, Tucumán Province, T4000AXL, Argentina
-
ARG009
Quilmes, Buenos Aires, B1878GEG, Argentina
-
AUT001
Vienna, 1090, Austria
-
AUT002
Linz, Upper Austria, 4020, Austria
-
BEL003
Brussels, 1070, Belgium
-
BRA002
Blumenau, Santa Catarina, 89030-101, Brazil
-
BRA004
Belo Horizonte, Minas Gerais, 30430-142, Brazil
-
BRA006
Porto Alegre, Rio Grande do Sul, 90035-003, Brazil
-
DNK001
Aarhus, Central Jutland, 8200, Denmark
-
ESP001
Santander, 39008, Spain
-
ESP003
Seville, 41009, Spain
-
GBR001
Bath, Avon, BA1 3NG, United Kingdom
-
GER002
Lübeck, Schleswig-Holstein, 23562, Germany
-
GER003
München, Bavaria, 80639, Germany
-
GER005
Heidelberg, Baden-Wurttemberg, 69126, Germany
-
ITA001
Palermo, 90127, Italy
-
ITA002
Pavia, Lombardy, 27100, Italy
-
ITA004
Roma, 00161, Italy
-
ITA005
Monza, 20900, Italy
-
JPN002
Okayama, Okayama-ken, 701-1192, Japan
-
JPN003
Suita-Shi, Osaka, 564-8565, Japan
-
JPN004
Sapporo, Hokkaido, 060-8648, Japan
-
JPN005
Sapporo, Hokkaido, 060-8543, Japan
-
JPN006
Tsukuba, Ibaraki, 305-9576, Japan
-
JPN007
Kurume-shi, Hukuoka, 830-0011, Japan
-
MEX001
Monterrey, Nuevo León, 64718, Mexico
-
MEX003
Mexico City, 14080, Mexico
-
MEX004
San Luis Potosí City, 78250, Mexico
-
MEX005
Lomas de Guevara, Jalisco, 44657, Mexico
-
MYS002
Kuantan, Pahang, 25200, Malaysia
-
MYS004
Sungai Buloh, Selangor, 47000, Malaysia
-
MYS005
Alor Star, Kedah, 5460, Malaysia
-
PHL001
Quezon City, National Capital Region, 1100, Philippines
-
PHL002
Makati City, 1229, Philippines
-
SRB001
Belgrade, 11000, Serbia
-
SRB003
Belgrade, 11000, Serbia
-
USA001
Chicago, Illinois, 60612, United States
-
USA005
Jacksonville, Florida, 32224, United States
-
USA006
Chicago, Illinois, 60611, United States
-
USA011
Tampa, Florida, 33606, United States
-
USA016
Dallas, Texas, 75246, United States
-
USA102
New York, New York, 10021, United States
Conditions
Explore the condition pages connected to this study.